跳至主要内容
临床试验/JPRN-UMIN000005253
JPRN-UMIN000005253已完成未知

Effect of Metformin on the esRAGE levels in type 2 diabetic patients: the Metformin Sitagliptin Randomized Trial - METS trial

Osaka City University Graduate School of Medicine, Metabolism, Endocrinology, and Molecular Medicine0 个研究点目标入组 60 人开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)The use of oral hypoglycemic agents, insulin preparations adrenocorticosteroid within 12 weeks prior to the start of observation period. 2)Patients with severe ketosis, diabetic coma, or with precoma 3)Patients with severe infections, before or after operation, or with serious trauma. 4)AST, ALT <=2.5 x Upper limit of facility reference at most recent of the registration, or patients with hepatic cirrhosis. 5)Patients with renal impairment.(Diabetic nephropathy staging >=stage3B before registration.) 6)Serve cardiovascular or pulmonary disorders, including shock, heart failure, myocardial infarction, lung infarction etc., or other conditions that are apt to cause hypoxemia. 7) Patients suffering from malnutrition, inanition, debility, pituitary gland malfunction, or adrenal gland dysfunction. 8)History of lactic acidosis. 9)Patients with a malignant tumor treated now. 10)History of hypersensitivity to biguanide oral hypoglycemic agent or DPP-4 inhibitor. 11)Pregnant women or women suspected of being pregnant. 12)Other patients determined to be inappropriate by physician.

研究者

发起方
Osaka City University Graduate School of Medicine, Metabolism, Endocrinology, and Molecular Medicine

相似试验

Effect of Metformin on the esRAGE levels in type 2... | 临床试验